Abstract

A STUDY TO COMPARE THE EFFICACY AND SAFETY OF BREXPIPRAZOLE AND CARIPRAZINE DRUG TREATMENT FOR SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Rajesh Kumar*, Krishan Pal, Anju Pal and Nitin Goel

Abstract

Introduction: A wide variety of atypical antipsychotic drugs (Thorazine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, haloperidol, prolixin, navane, loxapine, stelazine, trilafon, and mellaril and clozapine) are widely used in the management of neuropsychiatric symptoms, which are commonly seen in Schizophrenia. We aimed to review the efficacy and safety of atypical antipsychotic drugs (Brexpiprazole and Cariprazine) on neuropsychiatric symptoms in Schizophrenia patients. Methods: PubMed, EMBASE, and the Cochrane Database of Systematic Reviews for reports published before August 2015 were searched for eligible randomized controlled trials of atypical antipsychotic drugs therapy in patients with psychotic symptoms of Schizophrenia. Results: Overall, 4 relevant RCTs with more than 1700 participants were identified. This meta-analysis demonstrated a significant efficacy of Brexpiprazole and Cariprazine on psychiatric symptoms and PANSS score compared to placebo. In the meta-analysis, 95% confidence interval value were -16.03 to 11.81 and -9.355 to 16.00 with Std. Error 0.2394. Conclusion: Brexpiprazole and Cariprazine are able to improve PANSS Score at average 6 weeks in patients with neuropsychiatric symptoms of Schizophrenia. However, high adverse events may offset the efficacy of atypical antipsychotics in Schizophrenia. We need to more phase III studies data to identify who is superior.

Keywords: Thorazine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, Thorazine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, Thorazine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, Thorazine, risperidone, olanza